RIDDLE&CODE
17.3.2022 10:17:06 CET | Business Wire | Press release
The consortium formed by Dyne.org, RIDDLE&CODE and InfoCert has entered the second phase of the European Blockchain Services Infrastructure (EBSI) project and will receive support to further develop and test its multilayered blockchain stack ZENBRIDGE.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20220317005181/en/
Led by the European Commission and 29 member countries that collaborate as a European Blockchain Partnership (EBP), EBSI aims to develop highly secure and compliant cross-border public services on a European level. This involves overcoming gaps in the existing blockchain applications and delivering more demanding solutions that reduce environmental footprint and comply with EU legal frameworks such as the GDPR. The second phase of the project was launched on December 20, 2021, and will run until the end of June 2022.
Some use cases include management and exploitation of data, tracking of digital records and the rights associated with them, automation of tasks through smart contracts and development of incentive models through tokenization of both physical and digital assets.
ZENBRIDGE, a state-of-the-art decentralized system, offers distributed, secure execution of smart contracts and is integrated with blockchain frameworks such as BigchainDB, PlanetMINT, Ethereum, Hyperledger Fabric, Hyperledger Sawtooth and Bitcoin. The system is designed to deliver high-velocity performance, ensure sustainability and provide superior levels of data sovereignty as well as interoperability between various blockchain networks and legacy systems.
During this second phase, research and development results will be lab-tested. Based on these outcomes, a minimum of three projects will be selected for the final Phase (2B), which will run for an additional 12 months and result in real-world field testing.
Quotes from the consortium members:
Thomas Fürstner (Founder & CTO, RIDDLE&CODE): “The expertise of our consortium will hopefully convince the European Commission to make use of blockchain technology as a multipurpose tool to secure both the value of digital assets and data. At the ‘layer zero’, RIDDLE&CODE will work to connect productive machines and sensors with the security of banking-grade backends. This will allow us to establish trusted digital product passports for physical items in motion across Europe and ensure compliance with the European regulatory frameworks in a transparent way.”
Denis “Jaromil” Roio , (Founder and CTO of Dyne.org): “In our success within the EBSI procurement process, we see a big opportunity to provide the European ICT industry with environmentally sustainable solutions that are free and open to community-based adoption models. We leverage cryptography beyond some common financial sector use cases, making it easy to retrofit and recycle legacy infrastructure. Our solution is free from the speculation and waste of crypto-markets, supports computation on low-power embedded hardware and supports future-proof building blocks that are quantum-resistant. With the ZENBRIDGE stack, a developer can go from a smart contract to a ready-to-use wallet app implementation for digital product passports in a week.”
Carmine Auletta (Chief Strategy and Innovation Officer, InfoCert - Tinexta Group): “We’re pleased with the results achieved by the consortium in Phase 1 and proud of the support and trust placed in us to further develop the project in its second phase. Distributed Ledger Technologies will play an important role in the EU digital market and a key component to their market uptake will inevitably be played by their Governance & Trust Framework. Our consortium partners have demonstrated extraordinary technical expertise in distributed ledger technologies, while InfoCert has very distinctive experience in creating Trust Frameworks. Joining forces has proved crucial to ZENBRIDGE’s success.”
About RIDDLE&CODE
RIDDLE&CODE is Europe’s leading company for blockchain interface solutions. The company develops hardware and software stacks that combine the security of smart cards with blockchain and the Internet of Things (IoT). Together with its tier-one clients and partners, which include Daimler Mobility, BMW, Wien Energie and leading Dutch crypto exchange LiteBit, RIDDLE&CODE brings new business models to the fintech, energy, mobility and materials industries.
More information: www.riddleandcode.com
About Dyne.org
Dyne.org is a non-profit foundation dedicated to free and open-source software and community development with 20 years of expertise in developing applications used worldwide. With the motto “we are free to share code and we code to share freedom”, its projects include independent streaming software for free speech, privacy tools for activists and GNU/Linux distributions.
More information: dyne.org
About InfoCert
InfoCert, Tinexta Group, is the largest European certification authority, active in over twenty countries. The company provides services in digitisation, eDelivery, Digital Signature and digital preservation of documents and is an accredited AgID digital identity operator in the area of SPID (Public System for the management of Digital Identity). The company holds a 60% stake in CertEurope, the biggest certification authority in France; a 51% stake in Camerfirma, one of the principal Spanish certification authorities; a 16.7% stake in Authada, a leading-edge German Identity Provider; and 80% of Sixtema S.p.A.
More information: infocert.digital
View source version on businesswire.com: https://www.businesswire.com/news/home/20220317005181/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release
Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he
Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release
Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co
Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release
Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth
Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release
Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th
CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release
The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom